Human lymphoblastoid interferon for the treatment of chronic hepatitis B. A randomized controlled trial.
The aim of this study was to demonstrate whether interferon alone could affect the course of chronic hepatitis B. A total of 66 patients have so far been randomly assigned to receive six months of interferon therapy or no therapy; three patients in the interferon group and two in the control group have withdrawn from the study. Loss of hepatitis B virus-DNA and hepatitis B e antigen was significantly higher in the patients receiving interferon than in the control group; a significant loss of hepatitis B surface antigen was observed only in patients who received interferon. The time to alanine aminotransferase normalization was significantly shorter in patients receiving interferon than in the control group. These data encourage the use of interferon in treatment of chronic hepatitis B.
D000328:Adult; D002986:Clinical Trials as Topic; D004279:DNA, Viral / Q000097:blood; D005260:Female; D006509:Hepatitis B / Q000628:therapy*; D006513:Hepatitis B e Antigens / Q000032:analysis; D006515:Hepatitis B virus / Q000235:genetics; D006521:Hepatitis, Chronic / Q000628:therapy*; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D008111:Liver Function Tests; D008297:Male; D011897:Random Allocation
D004279:DNA, Viral; D006513:Hepatitis B e Antigens; D007370:Interferon Type I